181 related articles for article (PubMed ID: 19382113)
1. MAOA gene polymorphisms and response to mirtazapine in major depression.
Tzeng DS; Chien CC; Lung FW; Yang CY
Hum Psychopharmacol; 2009 Jun; 24(4):293-300. PubMed ID: 19382113
[TBL] [Abstract][Full Text] [Related]
2. Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.
Lee HY; Kang RH; Paik JW; Jeong YJ; Chang HS; Han SW; Lee MS
Brain Res; 2009 Mar; 1262():1-6. PubMed ID: 19401164
[TBL] [Abstract][Full Text] [Related]
3. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
[TBL] [Abstract][Full Text] [Related]
4. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N
Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843
[TBL] [Abstract][Full Text] [Related]
5. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
[TBL] [Abstract][Full Text] [Related]
6. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
7. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression.
Kang RH; Chang HS; Wong ML; Choi MJ; Park JY; Lee HY; Jung IK; Joe SH; Kim L; Kim SH; Kim YK; Han CS; Ham BJ; Lee HJ; Ko YH; Lee MS; Lee MS
J Psychopharmacol; 2010 Dec; 24(12):1755-63. PubMed ID: 19493959
[TBL] [Abstract][Full Text] [Related]
8. Mirtazapine for treatment-resistant depression: a preliminary report.
Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder.
Kasper S; Montgomery SA; Möller HJ; van Oers HJ; Jan Schutte A; Vrijland P; van der Meulen EA
World J Biol Psychiatry; 2010 Feb; 11(1):36-44. PubMed ID: 20146649
[TBL] [Abstract][Full Text] [Related]
10. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
Honig A; Kuyper AM; Schene AH; van Melle JP; de Jonge P; Tulner DM; Schins A; Crijns HJ; Kuijpers PM; Vossen H; Lousberg R; Ormel J;
Psychosom Med; 2007; 69(7):606-13. PubMed ID: 17846258
[TBL] [Abstract][Full Text] [Related]
11. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder.
Lee SH; Lee KJ; Lee HJ; Ham BJ; Ryu SH; Lee MS
Psychiatry Clin Neurosci; 2005 Apr; 59(2):140-5. PubMed ID: 15823158
[TBL] [Abstract][Full Text] [Related]
12. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
13. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder.
Chang HS; Lee HY; Cha JH; Won ES; Ham BJ; Kim B; Lee MS
J Clin Psychopharmacol; 2014 Aug; 34(4):446-54. PubMed ID: 24911443
[TBL] [Abstract][Full Text] [Related]
14. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients.
Laakmann G; Hennig J; Baghai T; Schüle C
Ann N Y Acad Sci; 2004 Dec; 1032():279-82. PubMed ID: 15677428
[TBL] [Abstract][Full Text] [Related]
15. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.
Tadić A; Müller MJ; Rujescu D; Kohnen R; Stassen HH; Dahmen N; Szegedi A
Am J Med Genet B Neuropsychiatr Genet; 2007 Apr; 144B(3):325-31. PubMed ID: 17192957
[TBL] [Abstract][Full Text] [Related]
16. A monoamine oxidase B gene variant and short-term antidepressant treatment response.
Tadić A; Rujescu D; Müller MJ; Kohnen R; Stassen HH; Dahmen N; Szegedi A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1370-7. PubMed ID: 17640790
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression.
Domschke K; Hohoff C; Mortensen LS; Roehrs T; Deckert J; Arolt V; Baune BT
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):224-8. PubMed ID: 17884271
[TBL] [Abstract][Full Text] [Related]
18. Association of MAO-A variant with complicated grief in major depression.
Kersting A; Kroker K; Horstmann J; Baune BT; Hohoff C; Mortensen LS; Neumann LC; Arolt V; Domschke K
Neuropsychobiology; 2007; 56(4):191-6. PubMed ID: 18337637
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
Kang EH; Lee IS; Chung SK; Lee SY; Kim EJ; Hong JP; Oh KS; Woo JM; Kim S; Park JE; Yu BH
Psychiatry Res; 2009 Sep; 169(2):118-23. PubMed ID: 19695711
[TBL] [Abstract][Full Text] [Related]
20. Genetic pathway of major depressive disorder in shortening telomeric length.
Lung FW; Chen NC; Shu BC
Psychiatr Genet; 2007 Jun; 17(3):195-9. PubMed ID: 17417064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
